The Journal of Practical Medicine ›› 2022, Vol. 38 ›› Issue (17): 2216-2220.doi: 10.3969/j.issn.1006⁃5725.2022.17.018

• Drugs and Clinic Practice • Previous Articles     Next Articles

Fondaparinux sodium versus enoxaparin sodium in the prevention of pulmonary thromboembolism

LI Xue⁃ mei，NIE Xiaohong，XIANG Lili，ZHANG Meifeng.   

  1. Department of Pulmonary and Critical Care Medicine，the Second Affiliated Hospital of Chengdu Medical College，Chengdu 610051，China

  • Online:2022-09-10 Published:2022-09-10
  • Contact: NIE Xiaohong E⁃mail：xhnie1226@sina.com

Abstract:

Objective To compare the efficacy and safety of fondaparinux sodium with those of enoxaparin sodium in the prevention of pulmonary thromboembolism（PTE）in hospitalized patients in the department of pulmo⁃ nary and critical care medicine（PCCM）. Methods The patients with indicationsofdrug prevention forPTE inthe PCCM of our hospital during the period of May，2020 to June，2021（23 in fondaparinux group and 71 in enoxaparin group）received subcutaneous injections of either 0.5 mL fondaparinux sodium or 0.4 mL enoxaparin sodium for 7 to 12 days. Platelet，D⁃dimer，liver and renal function，and Padua score before and after anti⁃coagulation，the inci⁃ dence of bleeding during anticoagulation and the incidence of PTE within 6 months after discharge in both groups were observed. Results There were no significant differences in platelet，D⁃dimer，liver andrenal function，and Padua score between the two groups before and after anti⁃coagulation（P > 0.05）. There were no significant differ⁃ ences in hospitalization expenses，bleeding incidence（3/23 vs. 10/71）and PTE incidence within 6 months after discharge（5/23 vs. 17/71）between the two groups（P > 0.05）. Level of D⁃dimer after anti⁃coagulation was signifi⁃ cantly lower than the baseline in the two groups（P < 0.001）. As compared with the baselines，there were statisti⁃ cal differences in declined platelet countand increased creatinine levelafter treatment with anti ⁃ coagulation in enoxaparin group（t = 2.858，P = 0.006 and t = -2.400，P = 0.019 respectively），while no significant changes in platelet countand creatinine levelin fondaparinux groupwere found. Conclusions Fondaparinux sodium and enoxa⁃ parin sodium had similar efficacy inthe prevention of PTE. The risk of bleeding during hospitalization and the rate of PTE within 6 months were similar. Fondaparinux sodium had more advantages than enoxaparin sodium in causin⁃ ga decrease in platelet count and an increase in creatinine.

Key words:

fondaparinux sodium, enoxaparin, prevention, pulmonary thromboembolism, curative effect, safety